CHERYL HUBER: Open Payments
NPI 1114025855 · BISMARCK, ND. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$329 in 15 payments from 11 companies in 2025. Trend: 2023 $188 · 2024 $214 · 2025 $329
Food & beverage: $304Education: $25
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 1 | $46 |
| Alkermes, Inc. | 2 | $36 |
| Neurocrine BioSciences, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $19 |
| ACADIA Pharmaceuticals Inc | 1 | $18 |
Products named: REXULTI, FANAPT, ARISTADA, INGREZZA, CAPLYTA, COBENFY, Auvelity, UZEDY.
Industry payments across ND — which companies pay providers there.
